A rare frameshift variant in trans with the IVS9-5T allele of CFTR in a Chinese pedigree with congenital aplasia of vas deferens
- 42 Downloads
Congenital aplasia of vas deferens (CAVD) is an atypical form of cystic fibrosis (CF) and causes obstructive azoospermia and male infertility. Compound heterozygous variants of CFTR are the main cause of CAVD. However, most evidence comes from genetic screening of sporadic cases and little is from pedigree analysis. In this study, we performed analysis in a Chinese pedigree with two CAVD patients in order to determine the genetic cause of this familial disorder.
In the present study, we performed whole-exome sequencing and co-segregation analysis in a Chinese pedigree involving two patients diagnosed with CAVD.
We identified a rare frameshift variant (NM_000492.3: c.50dupT;p.S18Qfs*27) and a frequent CBAVD-causing variant (IVS9-TG13-5T) in both patients. The frameshift variant introduced a premature termination codon and was not found in any public databases or reported in the literature. Co-segregation analysis confirmed these two variants were in compound heterozygous state. The other male members, who harbored the frameshift variant and benign IVS9-7T allele, did not have any typical clinical manifestations of CF or CAVD.
Our findings may broaden the mutation spectrum of CFTR in CAVD patients and provide more familial evidence that the combination of a mild variant and a severe variant in trans of CFTR can cause vas deferens malformation.
KeywordsCFTR CBAVD Compound heterozygous Chinese pedigree
This work was supported by funds from the National Natural Science Foundation of China (grant numbers 81671448 and 81871152).
Compliance with ethical standards
Written informed consent was obtained from all participants. This research was approved by the Research Ethics Committee of the Affiliated Hospital of Zunyi Medical University.
Conflict of interest
The authors declare that they have no competing interests.
- 7.Patat O, Pagin A, Siegfried A, Mitchell V, Chassaing N, Faguer S, et al. Truncating mutations in the adhesion g protein-coupled receptor G2 gene ADGRG2 cause an X-linked congenital bilateral absence of vas deferens. Am J Hum Genet. 2016;99(2):437–42. https://doi.org/10.1016/j.ajhg.2016.06.012.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Davies B, Baumann C, Kirchhoff C, Ivell R, Nubbemeyer R, Habenicht UF, et al. Targeted deletion of the epididymal receptor HE6 results in fluid dysregulation and male infertility. Mol Cell Biol. 2004;24(19):8642–8. https://doi.org/10.1128/MCB.24.19.8642-8648.2004.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Sobel RE, Bate A, Marshall J, Haynes K, Selvam N, Nair V, et al. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System’s analytic tools. Pharmacoepidemiol Drug Saf. 2018;27(3):332–9. https://doi.org/10.1002/pds.4392.CrossRefPubMedGoogle Scholar
- 13.Cai H, Qing X, Niringiyumukiza JD, Zhan X, Mo D, Zhou Y, et al. CFTR variants and renal abnormalities in males with congenital unilateral absence of the vas deferens (CUAVD): a systematic review and meta-analysis of observational studies. Genet Med. 2019;21(4):826–36. https://doi.org/10.1038/s41436-018-0262-7.CrossRefPubMedGoogle Scholar
- 15.Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest. 1998;101(2):487–96. https://doi.org/10.1172/JCI639.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Feng JR, Zhang YN, Wu X, Yang XJ, Chen ST, Ma GC, et al. Homozygous 5T alleles, clinical presentation and genetic analysis within a family with congenital bilateral absence of the vas deferens. Zhonghua Yi Xue Za Zhi. 2018;98(18):1414–8. https://doi.org/10.3760/cma.j.issn.0376-2491.2018.18.009.CrossRefPubMedGoogle Scholar
- 22.Chu CS, Trapnell BC, Curristin SM, Cutting GR, Crystal RG. Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest. 1992;90(3):785–90. https://doi.org/10.1172/JCI115952.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet. 2004;74(1):176–9. https://doi.org/10.1086/381001.CrossRefPubMedGoogle Scholar
- 24.Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30.CrossRefPubMedPubMedCentralGoogle Scholar